VIR NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Vir Biotechnology Inc · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 8.66 USD
-0.3% latest week
Weekly setup

Mixed setup

The weekly trend is active. Price is -1.6% below the Trend Line and sits at 60.0% of its 52-week range. The latest completed week returned -0.3%, after a -13.7% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks strongly; valuation is neither clearly cheap nor expensive. Options positioning is bullish with 43/100 conviction, while the latest news-sentiment score is 52/100. Near-term considerations: volume confirmation is below normal; earnings are due in 3d.

Setup score 43 out of 100
Latest Close 8.66 USD 31 Jul 2026
1W Return -0.3% latest completed week
4W Return -13.7% short-term follow-through
12W Return -5.0% quarterly tape
Trend Breadth 78.8% 41 of 52 weeks active
Volume Ratio 0.8x vs 13-week average
What is working
  • The trend backdrop is active with a 41-week active streak.
  • Price is above Fair Value, showing premium demand versus the model.
What could go wrong
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Activity pressure is negative, which weakens the current setup.
  • Next-week expectancy is negative at 40.42% based on similar historical setup states.
  • The share remains more than 20% below its 52-week high.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -0.3% Latest completed week; four-week move -13.7%. Indicator stack 88/29 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 40.42% Historical one-week expectancy contributes to the evidence score when direction is confirmed. Options pressure Bullish 43/100 conviction; expected move 26.0%. News sentiment 52/100 68 relevant articles in the latest sentiment read. Event risk 3d Next report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is -1.6% below the Trend Line and sits at 60.0% of its 52-week range. The latest completed week returned -0.3%, after a -13.7% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.8x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.5112-week average 0.64

12-week confirmation

Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure2/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.51Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -13.7% over four weeks, -5.0% over 12 weeks, and 72.2% over one year. The current trend has remained active for 41 consecutive weeks.

Performance by holding period

1W-0.3%
4W-13.7%
12W-5.0%
26W16.4%
52W72.2%
Active trend streak41 weeks
Active weeks in one year41
Trend breadth78.8%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-0.70Latest activity-pressure read.
Pressure change-99.7%Four-week change in activity pressure.
Leadership7.77Latest relative-leadership reading.
RS change-66.8%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks strongly; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 82% Model confidence 78%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength20/100Blend of value, momentum, and quality. Underlying universe rank 81; rank 1 is best.
Value25/100Relative valuation strength. Underlying universe rank 76; rank 1 is best.
Quality4/100Profitability and accounting quality. Underlying universe rank 97; rank 1 is best.
Momentum88/100Medium-term price momentum. Underlying universe rank 13; rank 1 is best.
Growth90/100Revenue and earnings growth. Underlying universe rank 11; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
22.4x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-34.1%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
275.2%
Gross profit retained from each unit of revenue.
Operating margin
-687.3%
Operating profit retained from revenue.
Free-cash-flow margin
-669.2%
Free cash flow generated from revenue.
Return on invested capital
-53.4%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
214.0%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
3/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
0.0%
Net share repurchases relative to market value.
Shareholder yield
0.0%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.4x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningBullish

VIR shows bullish options pressure with a 43/100 conviction score, put-call volume ratio of 0.38, expected move of 26.0%, and Sharemaestro trend signal active.

Conviction43/100
Expected move26.0%
Put/call volume0.38
Pressure51
Speculation3
Volatility93
Trend agreement47
Open options detail
Insider activity15 / 4

15 acquisitions and 4 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment52/100

Weighted news tone is neutral across 68 relevant articles.

15 positive · 44 neutral · 9 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings3dNext report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
Options expected move26.0%Nearest-chain priced movement where available.
52-week drawdown-25.7%Distance below the 52-week high.
13-week volatility5.7%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher12 of 2614 weeks finished lower.
Best week+20.2%Week of 27 Feb.
Worst week-9.3%Week of 5 Jun.
Latest week-0.3%Week of 31 Jul.

Shape of recent returns

Strong gains8
Modest gains4
Flat weeks0
Modest losses9
Sharp losses5
Recent vol5.7%13-week weekly-return volatility.
Base vol7.5%52-week weekly-return volatility.
Up/down split29/23Count of positive and negative weeks in the 52-week window.
Average skew6.2% / -4.9%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape50/100

Trend, activity pressure, participation, and risk combine to a 50/100 tape read.

 Indicator analysis65/100

Latest 12-week confirmation: trend 12/12, activity pressure 2/12, relative leadership 12/12.

Activity pressure 0.51; No reversal markers Next-Week ExpectancyNegative 40.42%

Next-week expectancy is negative with a 40.42% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors31/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 61; Small Cap Core rank 79 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options57/100

VIR shows bullish options pressure with a 43/100 conviction score, put-call volume ratio of 0.38, expected move of 26.0%, and Sharemaestro trend signal active.

Bullish · Call-side pressure · Expected move 26.0% Sentiment52/100

Weighted news tone is neutral across 68 relevant articles.

950,000 Shares in Vir Biotechnology, Inc. $VIR Bought by Avidity Partners Management LP Insiders15 / 4

15 acquisitions and 4 disposals in the latest 180-day insider tape.

 Earnings3d

Next report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 20268.66 USD-0.3%8.80 USD8.22 USD-0.707.776.8MOn
24 Jul 20268.69 USD-7.8%8.71 USD8.26 USD-0.479.368.3MOn
17 Jul 20269.43 USD-5.3%8.62 USD8.29 USD-0.2117.318.5MOn
10 Jul 20269.96 USD-0.8%8.50 USD8.32 USD-0.1719.527.8MOn
3 Jul 202610.04 USD0.1%8.39 USD8.41 USD-0.3523.386.7MOn
26 Jun 202610.03 USD9.5%8.27 USD8.49 USD-0.5325.2315.5MOn
19 Jun 20269.16 USD6.4%8.15 USD8.58 USD-0.6410.1114.6MOn
12 Jun 20268.61 USD-0.5%8.04 USD8.68 USD-0.676.707.2MOn
5 Jun 20268.65 USD-9.3%7.94 USD8.79 USD-0.5310.058.3MOn
29 May 20269.54 USD3.8%7.82 USD8.90 USD-0.2816.308.0MOn
22 May 20269.19 USD4.6%7.70 USD9.01 USD0.0415.957.5MOn
15 May 20268.79 USD-3.6%7.59 USD9.12 USD0.5013.027.6MOn
8 May 20269.12 USD-8.8%7.49 USD9.22 USD0.9817.628.5MOn
1 May 202610.00 USD-3.6%7.38 USD9.32 USD1.2936.637.0MOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.